Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?

BACKGROUND. Immune‐related adverse events (irAEs) have emerged as a serious clinical issue in the use of immune checkpoint inhibitors (ICIs). Risk factors for irAEs remain controversial. Therefore, we studied sex differences in irAEs in patients treated with anti‐programmed cell death protein 1 (PD‐...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Duma, Narjust, Abdel‐Ghani, Azzouqa, Yadav, Siddhartha, Hoversten, Katherine P., Reed, Clay T., Sitek, Andrea N., Enninga, Elizabeth Ann L., Paludo, Jonas, Aguilera, Jesus Vera, Leventakos, Konstantinos, Lou, Yanyan, Kottschade, Lisa A., Dong, Haidong, Mansfield, Aaron S., Manochakian, Rami, Adjei, Alex A., Dronca, Roxana S.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Immuno‐Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6853107/
https://ncbi.nlm.nih.gov/pubmed/31036771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0094
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados